OCT’s team have diverse backgrounds and bring together expertise across drug development, scientific research, and general management.

Dr John Lucas, Chief Commercial Officer

John is a pharmaceutical executive with over 20 years of experience, having previously held executive level management positions at Cizzle Biotechnology (as CEO), Silence Therapeutics (as General Counsel) and Ilika Plc (Vice President, Intellectual Property) with other experience at the National Cancer Institute and Boehringer Ingelheim Pharma. John has also run his own consulting business where he assisted clients with business and legal/patent matters in biotech-pharma. His experience includes deal-making, corporate and product strategy, operations, and patents.


John also has a wide range of subject matter experience including small molecule pharmaceuticals (including cannabinoids), RNA therapy, biologics, and diagnostics. John holds a law degree (JD) from George Washington University, a doctorate in molecular genetics from The Ohio State University, and a Master’s and Undergraduate degree in microbiology from Ohio University.

Dr Jutta Roth, Chief Scientific Officer

Jutta is responsible for driving the research strategy and IP development of OCT. With over fifteen years’ experience, Jutta previously served as Head of Strategic Development for Barts and The London School of Medicine and as Director of Partnerships for the Centre for Population Genomic Medicine in London, a collaboration between University College London, King’s College London and Queen Mary University of London. Having researched the potential of cannabinoids during her time at the University of Oxford, Jutta joined OCT to bring together academic and industry research in a competitive research programme.


Jutta has worked on various model organisms and has experience in a number of disease areas, including cardiovascular disorders, rare disorders, women’s health, and neuroscience. A published academic researcher, Jutta holds a PhD in Genetics with Distinction, and an MSc in microbiology, both from the University of Salzburg, with later research fellowships at Yale University and the National Institute for Medical Research.

Eugenia Shostak, Financial Controller

Eugenia is responsible for monitoring the financial position of both OCT and the company’s underlying research programs. A Chartered Professional Accountant with over ten years of experience, Eugenia has held previous positions at Deloitte LLP and Skill Capital LLP.